In this study, we describe results comparing the risk of ADRD in Medicare beneficiaries with rheumatoid arthritis (RA) who were treated with any of 3 targeted synthetic or biologic disease-modifying antirheumatic drugs (TDMARDs) identified in the hypothesis generation step as repurposing candidates: tofacitinib (a JAK inhibitor), tocilizumab (an IL-6 inhibitor), and TNF inhibitors, compared with an active comparator abatacept (a T-cell activation inhibitor) that is used for similar indication but was not found to be associated with changes in the JAK/STAT pathway in our omics studies. Here, TNF is linked to rheumatoid arthritis.